Experienced in Subacute Combined Degeneration

Dr. Mehmood H. Hashmi

Hematology Oncology | Hematology | Oncology
Cotton-O'neil Clinic Revocable Trust
1414 Sw 8th Ave, 
Topeka, KS 
Accepting New Patients
Offers Telehealth
Experienced in Subacute Combined Degeneration
Cotton-O'neil Clinic Revocable Trust
1414 Sw 8th Ave, 
Topeka, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mehmood Hashmi is a Hematologist Oncology specialist and a Hematologist in Topeka, Kansas. Dr. Hashmi is rated as an Experienced provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Familial Wilms Tumor 2, and Small Cell Lung Cancer (SCLC). Dr. Hashmi is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KS
Hospital Affiliations
Great Plains Of Sabetha
Coffey County Hospital
University Of Kansas Hospital
Stormont Vail Hospital
Languages Spoken
English
Hindi
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

COTTON-O'NEIL CLINIC REVOCABLE TRUST
1414 Sw 8th Ave, Topeka, KS 66606
Other Locations
COTTON-O'NEIL CLINIC REVOCABLE TRUST
909 Sw Mulvane St, Cotton O'neil Midtown, Topeka, KS 66606
COTTON-O'NEIL CLINIC REVOCABLE TRUST
6725 Sw 29th St, Topeka, KS 66614
COTTON-O'NEIL CLINIC REVOCABLE TRUST
1704 Commercial Cir, Wamego, KS 66547
COTTON-O'NEIL CLINIC REVOCABLE TRUST
2902 Sw Asbury Dr, Topeka, KS 66614
COTTON-O'NEIL CLINIC REVOCABLE TRUST
1516 Sw 6th Ave, Topeka, KS 66606
COTTON-O'NEIL CLINIC REVOCABLE TRUST
2909 Se Walnut Dr, Topeka, KS 66605
COTTON-O'NEIL CLINIC REVOCABLE TRUST
3520 Sw 6th Ave, Topeka, KS 66606
COTTON-O'NEIL CLINIC REVOCABLE TRUST
4505 Nw Fielding Rd, Topeka, KS 66618

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

3 Total Publications

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2024
Similar Doctors
Advanced in Subacute Combined Degeneration
Dr. Asha Murthy
Hematology Oncology | Hematology | Oncology
Advanced in Subacute Combined Degeneration
Dr. Asha Murthy
Hematology Oncology | Hematology | Oncology

Cotton-O'neil Clinic Revocable Trust

4505 Nw Fielding Rd, 
Topeka, KS 
 (5.2 miles away)
785-354-9591
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Asha Murthy is a Hematologist Oncology specialist and a Hematologist in Topeka, Kansas. Dr. Murthy is rated as an Advanced provider by MediFind in the treatment of Subacute Combined Degeneration. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Subacute Combined Degeneration, and Multiple Carboxylase Deficiency. Dr. Murthy is currently accepting new patients.

Advanced in Subacute Combined Degeneration
Dr. Christopher F. Sirridge
Hematology Oncology | Oncology | Hematology
Advanced in Subacute Combined Degeneration
Dr. Christopher F. Sirridge
Hematology Oncology | Oncology | Hematology

University Of Kansas Hospital Authority

12200 W 110th St, 
Overland Park, KS 
 (54.7 miles away)
913-574-2650
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Sirridge is a Hematologist Oncology specialist and an Oncologist in Overland Park, Kansas. Dr. Sirridge is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Hereditary Resistance to Anti-Vitamin K, Congenital Antithrombin 3 Deficiency, Protein C Deficiency, and Protein S Deficiency. Dr. Sirridge is currently accepting new patients.

Experienced in Subacute Combined Degeneration
Dr. Penelope J. Harris
Hematology Oncology | Oncology | Hematology
Experienced in Subacute Combined Degeneration
Dr. Penelope J. Harris
Hematology Oncology | Oncology | Hematology

Central Care PA

1401 W 12th Ave, 
Emporia, KS 
 (52.0 miles away)
620-342-1117
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Penelope Harris is a Hematologist Oncology specialist and an Oncologist in Emporia, Kansas. Dr. Harris is rated as an Advanced provider by MediFind in the treatment of Subacute Combined Degeneration. Her top areas of expertise are Breast Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Smoldering Multiple Myeloma. Dr. Harris is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hashmi's expertise for a condition
ConditionClose
    View All 36 Distinguished Conditions
    View All 38 Advanced Conditions
    View All 104 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile